<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04233580</url>
  </required_header>
  <id_info>
    <org_study_id>2019-1527</org_study_id>
    <nct_id>NCT04233580</nct_id>
  </id_info>
  <brief_title>Characterization of AmnioExcel Plus in Two Treatment Paradigms</brief_title>
  <official_title>Characterization of AmnioExcel Plus in Two Treatment Paradigms</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Texas Southwestern Medical Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Integra LifeSciences Corporation</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>University of Texas Southwestern Medical Center</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>Yes</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The Investigators plan to evaluate healing in two cohorts of patients with diabetic foot&#xD;
      wounds (n=20) that receive optimal treatment including serial wound debridement and&#xD;
      off-loading with a boot or postop shoe and AmnioEXCEL+. In one cohort, AmnioEXCEL+ will be&#xD;
      applied weekly at study visits and in the second cohort, AmnioEXCEL+ will be applied maximum&#xD;
      every 2 weeks (PRN, in the case that the wound requires debridement at a visit not intended&#xD;
      for AE+ application, the wound will be treated as SOC). In addition, the Investigators will&#xD;
      collect data on other potential confounding factors that could affect healing such as&#xD;
      antibiotic, anti-fungal and anti-infective medications, tobacco, comorbidities, diabetes&#xD;
      control, infection, perfusion, and activity. Wound healing, including wound size and adverse&#xD;
      events will be evaluated.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Study Procedures:&#xD;
&#xD;
      Collection of Demographic data, medical/social history Collection of medications1 Ankle&#xD;
      Brachial Index2 Wound debridement3 (standard of care procedure) Imaging with eKare4&#xD;
      Hyperspectral Imaging Application of study product&#xD;
&#xD;
        1. Only collect antibiotics, anti-fungal and anti-infective medications.&#xD;
&#xD;
        2. ABI (with toe pressure) can be done at screening or baseline.&#xD;
&#xD;
        3. Once wound is healed, wound debridement will not be done at weekly visits.&#xD;
&#xD;
        4. Once wound is healed, eKare will not be done at weekly visits.&#xD;
&#xD;
        5. EOS will occur on the date the subject is healed. *Screening and Visit 1 may be done on&#xD;
           the same day.&#xD;
&#xD;
      Screening and Enrollment*:&#xD;
&#xD;
        -  Review and sign the Informed Consent and HIPAA Authorization&#xD;
&#xD;
        -  Review the inclusion and exclusion criteria&#xD;
&#xD;
      If the subject qualifies for the study, they will participate in the following procedures&#xD;
      (weekly visits, +/-4 days):&#xD;
&#xD;
      Visit 1*:&#xD;
&#xD;
        -  Demographics (such as age, gender, race or ethnicity)&#xD;
&#xD;
        -  Past Medical History, Social History, Medications documented.&#xD;
&#xD;
        -  Labs documented as SOC within 6mo of initial visit&#xD;
&#xD;
        -  ABI with toe pressures2&#xD;
&#xD;
        -  Wound debridement&#xD;
&#xD;
        -  eKare wound measurement&#xD;
&#xD;
        -  Hyperspectral Imaging&#xD;
&#xD;
        -  Randomization&#xD;
&#xD;
        -  Application of AmnioEXCEL+&#xD;
&#xD;
        -  Source documentation&#xD;
&#xD;
        -  Stipend disbursement&#xD;
&#xD;
      Visits 2 through 6:&#xD;
&#xD;
        -  Wound debridement3&#xD;
&#xD;
        -  eKare wound measurement4&#xD;
&#xD;
        -  Hyperspectral imaging&#xD;
&#xD;
        -  Application of AmnioEXCEL+ per cohort assignment&#xD;
&#xD;
        -  Source documentation&#xD;
&#xD;
        -  Stipend disbursement&#xD;
&#xD;
      Visit 7:&#xD;
&#xD;
        -  Medications documented&#xD;
&#xD;
        -  Wound debridement3&#xD;
&#xD;
        -  eKare wound measurement4&#xD;
&#xD;
        -  Hyperspectral imaging&#xD;
&#xD;
        -  Application of AmnioEXCEL+ per cohort assignment&#xD;
&#xD;
        -  Source documentation&#xD;
&#xD;
        -  Stipend disbursement&#xD;
&#xD;
      Visits 8-11:&#xD;
&#xD;
        -  Wound debridement3&#xD;
&#xD;
        -  eKare wound measurement4&#xD;
&#xD;
        -  Hyperspectral Imaging&#xD;
&#xD;
        -  Application of AmnioEXCEL+ per cohort assignment&#xD;
&#xD;
        -  Source documentation&#xD;
&#xD;
        -  Stipend disbursement&#xD;
&#xD;
      Visit 12:&#xD;
&#xD;
        -  Wound debridement3&#xD;
&#xD;
        -  eKare wound measurement4&#xD;
&#xD;
        -  Source documentation&#xD;
&#xD;
        -  Stipend disbursement&#xD;
&#xD;
      End of Study (EOS) Visit 5:&#xD;
&#xD;
        -  Medications documented&#xD;
&#xD;
        -  Wound debridement3&#xD;
&#xD;
        -  eKare wound measurement4&#xD;
&#xD;
        -  Source documentation&#xD;
&#xD;
        -  Subject exit from study&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Active, not recruiting</overall_status>
  <start_date type="Actual">July 9, 2020</start_date>
  <completion_date type="Anticipated">June 1, 2022</completion_date>
  <primary_completion_date type="Actual">June 1, 2021</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Ekare wound measurement application to track wound healing.</measure>
    <time_frame>12 weeks</time_frame>
    <description>Incidence of healing at 12 weeks, tracked by wound measuring camera/app which performs a 3D measurement. This tracks rate of healing.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Ekare wound measurement application to track wound percent volume reduction</measure>
    <time_frame>12 weeks</time_frame>
    <description>Percent of volume reduction at 12 weeks, tracked by wound measuring camera/app which performs a 3D measurement and calculates the volume.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Ekare wound measurement application to track wound percent area reduction</measure>
    <time_frame>12 weeks</time_frame>
    <description>Percent of area reduction at 12 weeks, tracked by wound measuring camera/app which performs a 3D measurement and calculates the area.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Hyperspectral imaging camera to track wound bed perfusion.</measure>
    <time_frame>12 weeks</time_frame>
    <description>Hyperspectral imaging camera is used to track wound bed perfusion by calculating oxygenation and deoxygenation of the wound bed.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">40</enrollment>
  <condition>Diabetic Foot Ulcer</condition>
  <arm_group>
    <arm_group_label>Weekly AmnioEXCEL+ group</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>AmnioEXCEL+ will be applied weekly at study visits</description>
  </arm_group>
  <arm_group>
    <arm_group_label>PRN AmnioEXCEL+ group</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>AmnioEXCEL+ will be applied maximum every 2 weeks (PRN, in the case that the wound requires debridement at a visit not intended for AE+ application, the wound will be treated as SOC)</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Amnio Excel + weekly</intervention_name>
    <description>Amnio Excel + weekly</description>
    <arm_group_label>Weekly AmnioEXCEL+ group</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Amnio Excel + max every 2 weeks</intervention_name>
    <description>Amnio Excel + max every 2 weeks</description>
    <arm_group_label>PRN AmnioEXCEL+ group</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Criteria for Inclusion of Subjects:&#xD;
&#xD;
          -  21-90 years of age&#xD;
&#xD;
          -  Able to provide informed consent&#xD;
&#xD;
          -  Chronic foot ulceration below the ankle - persistent for &gt;30 days but &lt;6 months&#xD;
&#xD;
        Criteria for Exclusion of Subjects:&#xD;
&#xD;
          -  &lt;21 or &gt;90 years of age&#xD;
&#xD;
          -  Unable to provide informed consent&#xD;
&#xD;
          -  History of poor compliance in the opinion of the investigator&#xD;
&#xD;
          -  Gangrene&#xD;
&#xD;
          -  Untreated osteomyelitis&#xD;
&#xD;
          -  Widespread malignancy&#xD;
&#xD;
          -  Active alcohol or substance abuse such as cocaine, heroin, or methamphetamines that in&#xD;
             the opinion of the investigator will impact the subject's participation in the study&#xD;
&#xD;
          -  Pregnancy&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>21 Years</minimum_age>
    <maximum_age>90 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Lawrence Lavery, DPM MPH</last_name>
    <role>Principal Investigator</role>
    <affiliation>UT Southwestern Medical Center</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>UT Southwestern Medical Center at Dallas</name>
      <address>
        <city>Dallas</city>
        <state>Texas</state>
        <zip>75390</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>July 2021</verification_date>
  <study_first_submitted>January 14, 2020</study_first_submitted>
  <study_first_submitted_qc>January 16, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">January 18, 2020</study_first_posted>
  <last_update_submitted>July 19, 2021</last_update_submitted>
  <last_update_submitted_qc>July 19, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">July 20, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University of Texas Southwestern Medical Center</investigator_affiliation>
    <investigator_full_name>Larry Lavery</investigator_full_name>
    <investigator_title>Professor and Director of Research</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Diabetic Foot</mesh_term>
    <mesh_term>Foot Ulcer</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Chlorhexidine</mesh_term>
    <mesh_term>Chlorhexidine gluconate</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

